Levosimendan Fresenius Kabi

Levosimendan, the active ingredient in Levosimendan Fresenius Kabi, is a calcium sensitizer and potassium channel opener presented as an intravenous formulation for hospital use. It increases cardiac contractility and induces vasodilation in patients with acute decompensated heart failure.

GNH USA supplies Levosimendan Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and cardiac care units worldwide, with the product sourced from the European Union market. All shipments adhere to stringent quality standards and regulatory requirements.

Levosimendan is used as an inotropic agent for the management of acute decompensated heart failure.

Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion. Severe chronic heart failure with low output: provides short‑term hemodynamic support when conventional therapy is insufficient. Cardiogenic shock (adjunct): may be added to stabilize blood pressure and cardiac performance in critical care settings.

Levosimendan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure. - Nausea or vomiting: gastrointestinal discomfort. - Tachycardia: increased heart rate. - Dizziness: related to blood pressure changes. - Flushing: warm sensation on skin.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: reduced blood flow to heart muscle. - Severe hypotension: marked blood pressure fall requiring intervention. - Pulmonary edema: fluid accumulation in lungs. - Sudden cardiac death: rare but fatal outcome. - Anaphylactic reaction: severe allergic response.

Levosimendan requires careful monitoring and specific safety measures before and during therapy.

Monitor blood pressure: watch for hypotension and adjust infusion rate. Observe cardiac rhythm: detect arrhythmias promptly. Assess renal function: dose may need adjustment in severe impairment. Avoid concurrent strong vasodilators: risk of additive hypotensive effect. Use cautiously after recent myocardial infarction: potential for ischemia. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other cardiovascular agents, necessitating vigilance.

Major Interactions (Avoid): - Sodium nitroprusside: additive hypotensive effect. - Other inotropes (e.g., dobutamine): increased risk of arrhythmias. - Potassium channel blockers (e.g., nicorandil): excessive vasodilation.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt inotropic response. - ACE inhibitors or ARBs: potential for enhanced blood pressure reduction. - Diuretics: electrolyte shifts may affect cardiac stability.